Atlantic Union Bankshares Corp Boosts Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Atlantic Union Bankshares Corp boosted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 9.8% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,267 shares of the biopharmaceutical company’s stock after buying an additional 203 shares during the quarter. Atlantic Union Bankshares Corp’s holdings in Regeneron Pharmaceuticals were worth $2,383,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the business. Rakuten Securities Inc. raised its stake in shares of Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 19 shares in the last quarter. Stephens Consulting LLC acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter worth about $26,000. Sachetta LLC increased its stake in shares of Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 10 shares during the period. Lynx Investment Advisory purchased a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth approximately $33,000. Finally, Family Firm Inc. acquired a new stake in Regeneron Pharmaceuticals in the second quarter valued at approximately $33,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have commented on REGN shares. Truist Financial lowered their price target on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating for the company in a report on Friday, November 1st. Citigroup began coverage on Regeneron Pharmaceuticals in a report on Thursday, November 14th. They issued a “neutral” rating and a $895.00 target price on the stock. Wells Fargo & Company decreased their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating for the company in a report on Tuesday, October 22nd. Royal Bank of Canada dropped their price objective on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Finally, Evercore ISI dropped their price target on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $1,107.29.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $750.22 on Friday. The stock has a fifty day moving average price of $905.64 and a 200 day moving average price of $1,019.11. Regeneron Pharmaceuticals, Inc. has a 1-year low of $735.95 and a 1-year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The company has a market cap of $82.44 billion, a PE ratio of 18.57, a P/E/G ratio of 2.91 and a beta of 0.15.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.